首页> 美国卫生研究院文献>Frontiers in Pharmacology >Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients
【2h】

Bile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and Nutrients

机译:胆汁酸的合成:从自然到化学修饰与合成及其作为药物和营养物的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bile acids (BAs) are amphiphilic molecules with 24 carbon atoms and consist of a hydrophobic and a rigid steroid nucleus, to which are attached a hydrophilic hydroxyl group and a flexible acidic aliphatic side chain. The steroidal core of BAs constitutes a saturated cyclopentanoperhydrophenanthrene skeleton, consisting of three six-membered (A, B, and C) and one five-membered ring (D). Primary BAs are produced in the hepatocytes, while secondary BAs are formed by modifying the primary BAs in the intestinal lumen, i.e., by the reactions of 7α-dehydroxylation and deconjugation of cholic acid (CA) and chenodeoxycholic acid (CDCA). The most important secondary BAs are deoxycholic acid (DCA) and lithocholic acid (LCA). The BAs realize their effects through nuclear farnesoid X receptors (FXRs) and membrane TGR5 receptors. It has been found that BAs are also associated with other receptors such as the vitamin D receptor (VDR), from which the most significant ligand is calcitriol, as well as with pregnane X receptor (PXR) and potentially with the constitutive androstane receptor (CAR), whose ligands are numerous, structurally different xenobiotics that show greater affinity to BAs. The BAs as therapeutic agents (drugs) have the potential to produce beneficial effects in cases of sexually transmitted diseases, primary biliary cirrhosis (PBC), primary sclerosing cholangitis, gallstones, digestive tract diseases, cystic fibrosis, and cancer. Ursodeoxycholic acid (UDCA) was the only drug approved by the US Food and Drug Administration (FDA) for the treatment of PBC. In this paper, the different pathways of bile acid biosynthesis are explained as well as chemical modifications and the synthesis of different keto derivatives of BAs. Also, the effects of BAs on digestion of nutrients, their role as drugs, and, in particular, the emphasis on the hypoglycemic properties of 7α, 12α-dihydroxy−12–keto−5β-cholanic acid in the treatment of diabetes mellitus are examined in detail.
机译:胆汁酸(BAs)是具有24个碳原子的两亲性分子,由疏水性和刚性甾体核组成,亲水性羟基和柔性酸性脂族侧链与疏水性和刚性甾体核连接。 BA的甾体核心构成一个饱和的环戊基过氢菲骨架,由三个六元环(A,B和C)和一个五元环(D)组成。在肝细胞中产生初级BA,而通过修饰肠腔中的初级BA,即通过7α-脱羟基和胆酸(CA)和鹅去氧胆酸(CDCA)的脱结合反应形成次级BA。最重要的二级BA是脱氧胆酸(DCA)和石胆酸(LCA)。 BA通过核法呢基X受体(FXR)和膜TGR5受体实现其作用。业已发现,BAs还与其他受体有关,例如维生素D受体(VDR),其中最重要的配体是骨化三醇,还有孕烷X受体(PXR),还可能与组成型雄烷烃受体(CAR)相关。 ),其配体为多种结构不同的异生素,它们对BA的亲和力更高。作为治疗剂(药物)的BA具有在性传播疾病,原发性胆汁性肝硬化(PBC),原发性硬化性胆管炎,胆结石,消化道疾病,囊性纤维化和癌症中产生有益作用的潜力。熊去氧胆酸(UDCA)是美国食品和药物管理局(FDA)批准用于治疗PBC的唯一药物。在本文中,解释了胆汁酸生物合成的不同途径,以及BA的不同酮衍生物的化学修饰和合成。此外,还检查了BAs对营养物质消化的作用,其作为药物的作用,尤其是在糖尿病治疗中重点研究了7α,12α-二羟基-12-酮基-5β-胆酸的降血糖特性详细。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号